EudraCT-Nr.: 2022-502405-15-00
Rekrutierung gestartet
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)
Klinik für Innere Medizin II
Arnold-Heller-Str. 3| 24105 Kiel
III. Medizinische Klinik und Poliklinik
Langenbeckstr. 1| 55131 Mainz
Medizinische Klinik und Poliklinik III
Marchioninistr. 15| 81377 München